Telecommunications Press Releases
SEE OTHER BRANDS

The latest telecommunications news from the world

Telecommunications Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Telecommunications Press Releases.

Press releases published on August 11, 2025

Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date July 31, 2025

Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date July 31, 2025

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of July 31, 2025, short interest in 3,285 Nasdaq Global MarketSM securities totaled 13,683,072,188 shares compared with 13,792,841,090 shares in 3,260 Global Market issues …

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today …

Main Street Financial Services, Corp. Announces Opening of Full-Service Branch in St. Clairsville, Ohio

Main Street Financial Services, Corp. Announces Opening of Full-Service Branch in St. Clairsville, Ohio

WOOSTER, Ohio, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Main Street Financial Services, Corp. (OTCQX: MSWV), the holding company for Main Street Bank, is pleased to announce the opening of a full-service branch in St. Clairsville, Ohio. The new location, situated …

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results …

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approval Capricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory …

Life360 Names COO Lauren Antonoff as Chief Executive Officer

Life360 Names COO Lauren Antonoff as Chief Executive Officer

Co-Founder Chris Hulls will serve as Executive Chairman of the Board Planned leadership succession signals continued investment in product innovation and growth SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Life360 (Nasdaq: LIF), the category-defining …

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates

Presented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C- …

ACV Announces Second Quarter 2025 Results

ACV Announces Second Quarter 2025 Results

Second quarter revenue of $194 million Second quarter GAAP net income (loss) of ($7) million Second quarter non-GAAP net income of $12 million Second quarter Adjusted EBITDA of $19 million Expects 2025 revenue of $765 million to $775 million, growth of 20% …

Synchronoss Technologies Reports Second Quarter 2025 Results

Synchronoss Technologies Reports Second Quarter 2025 Results

Second Quarter Revenue of $42.5 Million, Including 92.6% Recurring Revenue Received CARES Act Tax Refund in Full, Amounting to $33.9 Million Reaffirms All Full Year Guidance Metrics BRIDGEWATER, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Synchronoss …

Assertio Reports Second Quarter 2025 Financial Results

Assertio Reports Second Quarter 2025 Financial Results

Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, …

BioVie Inc. Announces Closing of $12 Million Public Offering

BioVie Inc. Announces Closing of $12 Million Public Offering

CARSON CITY, Nev., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and …

Quest Resource Holding Corporation Reports Second Quarter 2025 Financial Results

Quest Resource Holding Corporation Reports Second Quarter 2025 Financial Results

Generated $3.9 million in operating cash flow in the second quarter and reduced debt by $6.6 million year to date Posted sequential improvements in gross profits and adjusted EBITDA Roll out of Operational Excellence Initiatives is on track and continuing …

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 …

TELA Bio Reports Second Quarter 2025 Financial Results

TELA Bio Reports Second Quarter 2025 Financial Results

MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended …

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 million Transaction …

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase …

Fluence Energy, Inc. Reports Third Quarter 2025 Results; Reaffirms Fiscal Year 2025 Guidance

Fluence Energy, Inc. Reports Third Quarter 2025 Results; Reaffirms Fiscal Year 2025 Guidance

ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its …

Mercury Systems Reports Fourth Quarter and Fiscal 2025 Results

Mercury Systems Reports Fourth Quarter and Fiscal 2025 Results

Record Q4 FY25 Bookings of $341.5 million; book-to-bill of 1.25 Record backlog of $1.40 billion; up 6% year-over-year Q4 FY25 Revenue of $273.1 million; GAAP net income of $16.4 million; and adjusted EBITDA of $51.3 million Q4 FY25 Operating Cash Flow of $ …

MidCap Financial Investment Corporation Reports Financial Results for the Quarter Ended June 30, 2025

MidCap Financial Investment Corporation Reports Financial Results for the Quarter Ended June 30, 2025

Results for the Quarter Ended June 30, 2025 and Other Recent Highlights: Net investment income per share for the quarter was $0.39, compared to $0.37 for the quarter ended March 31, 2025 Net asset value per share as of the end of the quarter was $14.75, …

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026 Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDA Company accelerates Anaphylm global expansion strategy to Canada and the EU Company to host …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions